Revelation Biosciences, Inc.
Revelation Biosciences, Inc. (REVB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
revb · pe ratio · data through Jun 8, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Revelation Biosciences, Inc.You REVB | $4M | N/A | — | -$3.08 |
 Avenue Therapeutics, Inc. ATXI | $1M | N/A | — | -$0.93 |
 Azitra, Inc. AZTR | $2M | N/A | — | -$2.25 |
 GT Biopharma, Inc. GTBP | $5M | N/A | — | -$5.14 |
 Indaptus Therapeutics, Inc. INDP | $4M | N/A | — | -$21.58 |
 NKGen Biotech, Inc. Common Stock NKGN | $8M | N/A | — | -$1.54 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Revelation Biosciences, Inc. (REVB) measures how much investors pay for each dollar of the company's trailing earnings. REVB's current PE ratio of N/A is calculated by dividing its stock price of $1.01 by its TTM earnings per share of -$3.08.
Frequently asked questions
REVB pe ratio · 6 questionsREVB's current PE ratio is N/A as of 2026-06-08, based on a stock price of $1.01 and TTM EPS of -$3.08. Data sourced from Financial Modeling Prep via REVB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Revelation Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08